Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

SpringWorks Therapeutics, Inc. SWTX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
57/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$62.50
+33%

SpringWorks Therapeutics, Inc. (SWTX) is a Biotechnology company in the Healthcare sector, currently trading at $46.99. It has a SharesGrow Score of 57/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Analyst consensus target is SWTX = $63 (+33% upside).

Financials: revenue is $192M, +1703%/yr average growth. Net income is $258M (loss), growing at -18.8%/yr. Net profit margin is -134.7% (negative). Gross margin is 93.4% (+24.2 pp trend).

Balance sheet: total debt is $8M against $481M equity (Debt-to-Equity (D/E) ratio 0.02, conservative). Current ratio is 3.81 (strong liquidity). Debt-to-assets is 1.3%. Total assets: $587M.

Analyst outlook: 7 / 11 analysts rate SWTX as buy (64%) — moderate consensus.

SharesGrow 7-Criteria breakdown: Value 90/100 (Pass), Growth 58/100 (Partial), Past 0/100 (Fail), Health 100/100 (Pass), Moat 70/100 (Pass), Future 73/100 (Pass), Income 10/100 (Fail).

$62.50
▲ 33.01% Upside
Average Price Target
Based on 11 Wall Street analysts offering 12-month price targets for SpringWorks Therapeutics, Inc., the average price target is $62.50, with a high forecast of $78.00, and a low forecast of $47.00.
Highest Price Target
$78.00
Average Price Target
$62.50
Lowest Price Target
$47.00

SWTX SharesGrow Score Overview

67/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 90/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 70/100
Gross margin is + market cap
FUTURE 73/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — SWTX

✓
VALUE Pass
90/100
SWTX trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $63, implying +34.1% from the current price $47. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
SWTX: +1703%/yr revenue is, -18.8%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet SWTX: Debt-to-Equity (D/E) ratio 0.02 (conservative), Current ratio is 3.81 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
70/100
SWTX: Gross margin is 93.4% (+24.2 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 70/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
73/100
Analyst outlook: 7 / 11 analysts rate SWTX as buy (64%). Analyst consensus target is $63 (+34.1% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
SWTX: Net profit margin is -134.7%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range28.21-62
Volume5.01M
Avg Volume (30D)5.85M
Market Cap$3.54B
Beta (1Y)0.70
Share Statistics
EPS (TTM)-3.48
Shares Outstanding$74.13M
IPO Date2019-09-13
Employees368
CEOSaqib Islam
Financial Highlights & Ratios
Revenue (TTM)$191.59M
Gross Profit$179.04M
EBITDA$-278.13M
Net Income$-258.13M
Operating Income$-278.13M
Total Cash$307.99M
Total Debt$7.91M
Net Debt$-61.84M
Total Assets$587.28M
Price / Earnings (P/E)-13.5
Price / Sales (P/S)18.48
Analyst Forecast
1Y Price Target$62.50
Target High$78.00
Target Low$47.00
Upside+33.0%
Rating ConsensusBuy
Analysts Covering11
Buy 64% Hold 36% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS85205L1070

Price Chart

Track all markets on TradingView
SWTX
SpringWorks Therapeutics, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
28.21 52WK RANGE 62.00

People Also View

RVMD
RVMD
Revolution Medicines, Inc.
$147.01
+7.86%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 CERE
CERE
Cerevel Therapeutics Holdings, Inc.
$44.96
+0.74%
 KYMR
KYMR
Kymera Therapeutics, Inc.
$89.87
+1.51%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 MRTX
MRTX
Mirati Therapeutics, Inc.
$58.70
-0.17%
 RLAY
RLAY
Relay Therapeutics, Inc.
$14.75
-3.34%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message